Our mission is to collaboratively develop a registry of patients with pediatric onset aMG and CMS from which to determine best practices and identify areas in need of further research including clinical trials.
Peds MG Consortium
About the Consortium
The Pediatric Myasthenia Gravis Consortium (PMGC) was started to develop a registry of patients with both genetic forms of myasthenia gravis as well as the acquired autoimmune type. Experts from six initial centers around the country have developed a registry with which to follow these patients to determine best practices in the diagnosis and treatment of myasthenia gravis.
Goals of the Consortium:
1. Enhance Understanding of Myasthenia Gravis (MG) and Congenital Myasthenic Syndrome (CMS)
2. Optimize Health Outcomes
3. Expand Therapy Development
Who Can Participate
► All patients diagnosed with myasthenia gravis before the age of 18 years, either with the congenital or acquired form will be included. Patients can be enrolled from birth through adulthood, although they must be seen at one of the following pediatric centers to be enrolled:
- UCSF Benioff Children's Hospital
- Ann & Robert H. Lurie Children’s Hospital of Chicago
- Children’s Hospital of Philadelphia
- University of California, Davis
- University of Rochester
- UT Southwestern
►Interested in signing up? Please email our PMGC Study Coordinator, Ria Guerrero at [email protected].
►Still have questions? Please check out our FAQs page.